Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Download as docx, pdf, or txt
Download as docx, pdf, or txt
You are on page 1of 12

HEART FAILURE

Physiology of Cardiac Contractility

CONTRACTION: Action potential from the brain opens the L-type calcium
channels in myocardium, for trigger calcium to stimulate Ryanodine receptors in
SR. Stimulated RYR-II will induce sarcoplasmic Reticulum to release more calcium
ions in the cytoplasm of the heart. The Calcium ions will eventually bind to
myosin-actin filaments to contract the muscles
RELAXATION: For the muscle to relax. The calcium ions will diffuse back into
sarcoplasmic reticulum through Sarcoplasmic Endoplasmic reticulum ATPase
(SERCA) and Na-K+ ATPase pump. The Na-K+ ATPase pumps 2 potassium ions
inside the cytoplasm and 3 sodium ions outside the extracellular matrix. Once
Sodium ions are concentrated enough in the extracellular matrix; it will go back
again to the myocardium cells through Sodium-Calcium Exchanger (NCX)
Ejection Fraction
Heart Failure – is a long-term progressive effects in which the heart cannot pump out the blood in the
ventricles properly, resulting to accumulation of blood in the heart and may cause valve regurgitation.

CARDINAL SYMPTOMS OF HEART FAILURE

1. Dyspnea
a.. Dyspnea upon exertion
b. Orthopnea – Dyspnea when lying flat
c. Paroxysmal nocturnal – dyspnea when sleeping
2. Edema
A. Peripheral edema – the right side of the ventricle have difficulty in contracting due to large
amount of fluid (blood).
B. Pulmonary Edema – The left ventricle of the heart is affected because the lungs is
transferring too much fluid (blood)
3. Fatigue

Two types of heart failure

Diastolic heart failure Systolic Heart failure


The heart is contracting normally except the The left ventricle does not generate enough
ventricles are very stiff and do not relax properly contractile force thus there will be accumulation
and there is lesser amount of cardiac preload is of residual blood in the heart and it will
entering the heart. eventually build up over time.

Hypertrophy of heart muscles Ejection Fraction <45%


Stiffening of heart muscles
Normal ejection fraction – but there is a
significant reduce stroke volume since there is
not enough cardiac preload

Compensatory mechanism for Heart Failure

Due to weak ventricular


performance of the heart; it will
eventually result in less cardiac
preload and thus the brain will
activate sympathetic activity which
will enhance Sodium and H2O
retention to increase the blood
pressure, however it will also
increase the oxygen demand of
the heart.
1.) Decrease in Cardiac Output will trigger the release of Norepinephrine, Angiotensin II, and
endothelin to facilitate vasoconstriction. However, the vasoconstriction will cause the
heart to pump even more harder because the arteries also constrict.
2.) Due to increased pressure in artery; it will result again in decrease cardiac output and
then the substances such as NE will be released again
3.) This process repeats repeatedly and will eventually wear the heart muscles.

OTHER CAUSES OF HEART FAILURE

1. Hypertrophy – Enlargement of heart contractile heart cells due to ischemia and heart caspases
2. Remodeling– Structural changes in the heart i.e. dilation of left ventricles

CLASIFICATION OF HEART FAILURE IN NYHA


CLASSIFICATIONOF HEART FAILURE IN ACC/AHA
Pharmacologic goal of treatment in the heart failure

1. Decrease the workload of heart due to compensatory mechanisms


2. Increase the contractional ability of the heart so the blood will not accumulate in the ventricle

DRUGS FOR HEART FAILURE

POSITVE INOTROPES – Compounds that increases the contractile force of the myocardium

Drugs with inotropic effect Drugs without inotropic effect


Aka unloader mechanism – inhibits the
compensatory mechanism

(First line agent for Chronic HF)


Cardiac glycosides – digoxin ACE and ARBS
Beta-receptor stimulants – Dobutamine Diuretics – Thiazides
Bipyridines Vasodilators
- Inamrinone
- Milrinone
Beta-Blockers

Miscellaneous inotropic drugs

1. Istaroxime – Inhibits the NA+-K+ ATPase and facilitates the sequester of Calcium ions and
calmodulin
2. Levosimendan – Sensitize the troponin system to calcium and thus reduces PDE5
CARDIAC GLYCOSIDES
DIGITOXIN – Are not use anymore due to its long pharmacokinetics
DIGOXIN MOA: Are concentrated in the heart cells and inhibits the Na-K ATPase
to inhibit the NCX from functioning. Thus calcium ions will be retain in the
intracellular and further stimulates actin-myosin action.

Pharmacological effects of Digoxin

1. Cardiac effects
Mechanical effects – Enhance the level of calcium in the intracellular matrix of the heart thus
increasing contraction of sarcomere. The extra calcium ions will also be stored in SERCA, as a
reservoir. And so if trigger calcium stimulates RYR-II, SR can release calcium ions again
2. Electrophysiological effects (DOSE DEPENDENT)
THERAPEUTIC DOSE
A. Stimulates Central Vagus Nerve - Increase the refraction period of Atrio-ventricular node
thus it decrease the heart rate.
Vagus nerve also slows SA node
(Digoxin have positive inotropy and negative chronotropy)
B. Also decrease the sympathetic tone by activating baroreceptor

HIGH DOSE

Ventricular Tachycardia

Enhance automaticity
PLASMA CONCENTRATION OF DIGOXIN

3. Extra-cardial effect of Digoxin


 Most common is GIT disturbance such as N&V, Anorexia, Diarrhea
 Visual Disturbance = yellow-green visual discoloration
 Gynecomastia

Interactions of Digoxin to Ions


1. Potassium
A. HYPERKALEMIA – Reduces the effect of cardiac glycosides
B. HYPOKALEMIA – Facilitates the action of cardiac glycosides
2. Calcium
A. Hypercalcemia – Abnormal amount of trigger calcium and accumulation in the
intracellular myocardia cells
3. Magnesium
A. Hypomagnesemia – enhances the effect of digoxin because Magnesium are
considered as natural calcium channel blocker, and lower levels of it means more L-
type calcium channels are open. (NATURAL CCBs)
Drug Interactions of Digoxin
1. Additive effect – Amiodarone, Erythromycin, Quinidine, Tetracycline, Verapamil
2. Induces hypokalemia – Corticosteroids, Thiazide diuretics, Loop diuretics
Digoxin Toxicity Treatment
1. Withdraw the use of cardiac glycosides and drugs such as thiazides to prevent the
residual concentration of digoxin for further drug interaction.
2. Introduce KCl IV infusions or Magnesium to counter the effect of digoxin
3. Anti-arrhythmic drug
A. Phenytoin – Ventricular and Atrial Arrythmias
B. Lidocaine and Procainamide – Ventricular arrythmias
C. Propranolol – Ventricular and supraventricular arrythmias
D. Atropine – Sinus Bradycardia and AV blocks
4. DIGIBIND – An antibody that specifically binds and neutralize digoxin

BETA-1 AGONIST : Dobutamine MOA

1. Beta-Agonist stimulates Beta-1


receptors that will activate Gs
protein.
2. Gs Protein will stimulate Adenyl
cyclase from converting ATP into
c-AMP
3. Enhance level of c-AMP with
stimulate PK-A (protein kinase A)
4. PK-A facilitates the opening of L-
type calcium channel in the heart

Clinical Uses of Dobutamine

- Use as treatment for acute heart failure


- Unlike digoxin; it have a positive chronotropic and inotropic effect
Phosphodiesterase-3 inhibitors: (Bipyridines) Inamrinone and Milrinone
Function of PDE-5: Metabolize c-AMP
MOA OF PDE-5 Inhibitors: Inhibits PDE-5

Inamrinone and Milrinone


 Only used in ACUTE heart failure or severe exacerbation of chronic heart
failure
 IV administration only

Adverse effects of Inamrinone and Milrinone


 Arrythmias
 Hypotension
 Abdominal pain
 Fever
 Dizziness
 N&V
 Hepatotoxicity
 Thrombocytopenia
ACTION OF DIURETICS IN CHF
 Reduce venous return and ventricular preload by decreasing blood
volume and tone of veins
Spironolactone
Aldosterone antagonists
Prevents Potassium wasting especially when patient is on digoxin
ACTION OF ACE inhibitors in CHF
 Reduce preload
 Reduce afterload
 Reduce aldosterone secretion
 Inhibits cardiac and vascular remodeling
ACTION OF ARBs
These are ARBs drugs considered for HF: Losartan, Irbesartan, Candesartan
SPECIAL BETA-BLOCKERS FOR HEART FAILURE
 Blocks the Beta-mediated RAAS pathway
1. Bisoprolol
2. Carvedilol
3. Metoprolol succinate
4. Nebivolol

You might also like